Teva Calls In Sanofi To Turbocharge Its Place In Blockbuster TL1A Inflammation Race :: Scrip
BioSpace on LinkedIn: Sanofi, Teva Ink Potential $1.5B Deal Aimed at Blockbuster IBD Drug |…
Teva Stock Dives After Inking $1.5 Billion Deal For Inflammation Drug | Investor's Business Daily
Teva Weighs Sale of $2 Billion Active Ingredients Unit - BNN Bloomberg
Israel's Teva gives upbeat outlook as restructuring proceeds | The Seattle Times
Teva plans to sell Irvine drug plant – Orange County Register
Teva Pharmaceutical Shares Plunge After Quarterly Loss and 2018 Outlook Warning - WSJ
Teva's Blockbuster Drug Takes Another Generic Blow | Ctech
Teva to cut 14,000 jobs | Business | Chemistry World
Generic Copaxone launches in US - PMLiVE
Teva Pharmaceuticals: Value Play or Value Trap? | by Shivam Kollur | Medium
Teva files potential blockbuster migraine drug for FDA approval
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva Pharmaceutical's Sales Slump 18% - WSJ
Teva seeks to reinvent itself as branded drug developer - Globes
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Teva Is the 23rd Drug Maker to Impose Limits on 340B Contract Pharmacies - 340B Report
Generic-drug maker Teva steals market share from Big Pharma - Aug. 5, 2009
Teva Launches First Generic to Blockbuster Cancer Med
Teva & Barr Get Super-Sized
Sandoz and Teva invalidate blockbuster apixaban patent and SPC - JUVE Patent
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
A determined FDA takes down Teva's blockbuster | Evaluate
Pharma giant Teva looks to steady ship with new CEO in coming weeks | The Times of Israel
Teva's Stock Price Surge Against Its Predictable Woes
Teva Pharmaceuticals appoints Richard Francis CEO | HealthCare Middle East & Africa Magazine
/cloudfront-us-east-2.images.arcpublishing.com/reuters/G5JWOXLOQZIDLHFUUAR3HXPXEQ.jpg "Teva hopes Sanofi collaboration will lead to blockbuster IBD drug | Reuters")
Teva hopes Sanofi collaboration will lead to blockbuster IBD drug | Reuters
Teva agrees to buy Allergan's generics distribution unit
Allergan sells generic drug unit to Israel's Teva for $40.5 billion - Los Angeles Times
